{"id":66372,"date":"2026-05-26T22:10:49","date_gmt":"2026-05-26T14:10:49","guid":{"rendered":"https:\/\/flcube.com\/?p=66372"},"modified":"2026-05-26T22:10:51","modified_gmt":"2026-05-26T14:10:51","slug":"qingfeng-pharmaceutical-secures-greater-china-rights-to-merzs-inbrija-levodopa-inhalation-powder-for-parkinsons-disease-off-episodes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66372","title":{"rendered":"Qingfeng Pharmaceutical Secures Greater China Rights to Merz&#8217;s Inbrija Levodopa Inhalation Powder for Parkinson&#8217;s Disease OFF Episodes"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Qingfeng Pharmaceutical Group Co., Ltd.<\/strong> announced a <strong>licensing agreement<\/strong> with <strong>Merz Therapeutics GmbH<\/strong>, a German specialty pharmaceutical company, granting Qingfeng <strong>exclusive development and commercialization rights<\/strong> to <strong>Inbrija (levodopa inhalation powder)<\/strong> and its proprietary <strong>inhalation device<\/strong> for the <strong>intermittent treatment of on-off (OFF) episodes<\/strong> in adult patients with <strong>Parkinson&#8217;s disease (PD)<\/strong> across <strong>mainland China, Hong Kong, and Macau<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-strategic-framework\" class=\"wp-block-heading\">Deal Structure &amp; Strategic Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Partnership Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Qingfeng Pharmaceutical (licensee) \/ Merz Therapeutics (licensor)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Inbrija (levodopa inhalation powder) + inhalation device<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China, Hong Kong, and Macau (Greater China)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Intermittent treatment of OFF episodes in adult PD patients on levodopa\/DDCI therapy<\/td><\/tr><tr><td><strong>Qingfeng Responsibilities<\/strong><\/td><td>Local development, regulatory filing, commercialization, clinical funding<\/td><\/tr><tr><td><strong>Merz Responsibilities<\/strong><\/td><td>Product supply, global quality assurance, overseas drug registration holder<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Undisclosed upfront payment + development\/commercial milestones + tiered supply prices + royalties<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The partnership establishes a clear division of responsibilities leveraging Merz&#8217;s global manufacturing expertise and Qingfeng&#8217;s local regulatory and commercial capabilities.<\/p>\n\n\n\n<h2 id=\"h-asset-profile-amp-clinical-differentiation\" class=\"wp-block-heading\">Asset Profile &amp; Clinical Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Product:<\/strong> <strong>Inbrija (levodopa inhalation powder)<\/strong> \u2013 first-in-class inhaled levodopa formulation<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong> <strong>FDA approved (2018)<\/strong> and <strong>EMA approved (2019)<\/strong> for PD OFF episode management<\/li>\n\n\n\n<li><strong>Target Population:<\/strong> Adult PD patients already receiving <strong>levodopa\/dopa-decarboxylase inhibitor (DDCI) therapy<\/strong><\/li>\n\n\n\n<li><strong>Key Innovation:<\/strong> <strong>Pulmonary delivery<\/strong> bypasses gastrointestinal absorption issues common in PD<\/li>\n\n\n\n<li><strong>Clinical Advantage:<\/strong> <strong>Unaffected by food intake<\/strong> or PD-related GI conditions that interfere with oral medication absorption<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-parkinson-s-disease-market-opportunity\" class=\"wp-block-heading\">Parkinson&#8217;s Disease Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market Context<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>PD Prevalence in China<\/strong><\/td><td>Estimated 3-4 million patients; growing rapidly with aging population<\/td><\/tr><tr><td><strong>OFF Episode Burden<\/strong><\/td><td>40-60% of advanced PD patients experience unpredictable OFF episodes<\/td><\/tr><tr><td><strong>Current Treatment Gap<\/strong><\/td><td>Limited options for rapid rescue therapy during OFF episodes<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Oral rescue medications face absorption challenges; injectable options have compliance barriers<\/td><\/tr><tr><td><strong>Inbrija Differentiation<\/strong><\/td><td>Rapid onset (within minutes), non-invasive administration, reliable absorption regardless of GI status<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-commercial-strategy-amp-market-access\" class=\"wp-block-heading\">Commercial Strategy &amp; Market Access<\/h2>\n\n\n\n<h3 id=\"h-regulatory-pathway\" class=\"wp-block-heading\">Regulatory Pathway<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Local Registration:<\/strong> Qingfeng to lead NMPA submission leveraging existing FDA\/EMA approvals<\/li>\n\n\n\n<li><strong>Registration Holder Structure:<\/strong> Merz as overseas holder, Qingfeng as local responsible party<\/li>\n\n\n\n<li><strong>Accelerated Review Potential:<\/strong> Priority review possible given unmet medical need and established safety profile<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-commercial-infrastructure\" class=\"wp-block-heading\">Commercial Infrastructure<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Setting:<\/strong> Neurology clinics, movement disorder centers, and hospital pharmacies<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Premium pricing justified by innovative delivery and clinical benefits<\/li>\n\n\n\n<li><strong>Market Education:<\/strong> Significant investment required in physician and patient education on inhalation technique<\/li>\n\n\n\n<li><strong>Reimbursement Strategy:<\/strong> Pursuit of national reimbursement listing to ensure broad access<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-amp-industry-impact\" class=\"wp-block-heading\">Strategic Implications &amp; Industry Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage:<\/strong> Inbrija represents the first inhaled levodopa therapy in Greater China<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Success could establish Qingfeng as preferred partner for European CNS innovations<\/li>\n\n\n\n<li><strong>Investment Signal:<\/strong> Demonstrates continued international confidence in China&#8217;s specialty pharmaceutical market<\/li>\n\n\n\n<li><strong>Patient Impact:<\/strong> Addresses critical unmet need for reliable, rapid-acting OFF episode rescue therapy<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market penetration, and commercial performance. Actual results may differ due to risks including regulatory decisions, market adoption rates, competitive dynamics, and execution challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Qingfeng Pharmaceutical Group Co., Ltd. announced a licensing agreement with Merz Therapeutics GmbH, a German&#8230;<\/p>\n","protected":false},"author":1,"featured_media":66373,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4091,3939],"class_list":["post-66372","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-merz-therapeutics","tag-qingfeng-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Qingfeng Pharmaceutical Secures Greater China Rights to Merz&#039;s Inbrija Levodopa Inhalation Powder for Parkinson&#039;s Disease OFF Episodes - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Qingfeng Pharmaceutical Group Co., Ltd. announced a licensing agreement with Merz Therapeutics GmbH, a German specialty pharmaceutical company, granting Qingfeng exclusive development and commercialization rights to Inbrija (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of on-off (OFF) episodes in adult patients with Parkinson&#039;s disease (PD) across mainland China, Hong Kong, and Macau.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66372\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Qingfeng Pharmaceutical Secures Greater China Rights to Merz&#039;s Inbrija Levodopa Inhalation Powder for Parkinson&#039;s Disease OFF Episodes\" \/>\n<meta property=\"og:description\" content=\"Qingfeng Pharmaceutical Group Co., Ltd. announced a licensing agreement with Merz Therapeutics GmbH, a German specialty pharmaceutical company, granting Qingfeng exclusive development and commercialization rights to Inbrija (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of on-off (OFF) episodes in adult patients with Parkinson&#039;s disease (PD) across mainland China, Hong Kong, and Macau.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66372\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-26T14:10:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-26T14:10:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2601-2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66372#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66372\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Qingfeng Pharmaceutical Secures Greater China Rights to Merz&#8217;s Inbrija Levodopa Inhalation Powder for Parkinson&#8217;s Disease OFF Episodes\",\"datePublished\":\"2026-05-26T14:10:49+00:00\",\"dateModified\":\"2026-05-26T14:10:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66372\"},\"wordCount\":497,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66372#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2601-2.webp\",\"keywords\":[\"Merz Therapeutics\",\"Qingfeng Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66372#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66372\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66372\",\"name\":\"Qingfeng Pharmaceutical Secures Greater China Rights to Merz's Inbrija Levodopa Inhalation Powder for Parkinson's Disease OFF Episodes - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66372#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66372#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2601-2.webp\",\"datePublished\":\"2026-05-26T14:10:49+00:00\",\"dateModified\":\"2026-05-26T14:10:51+00:00\",\"description\":\"Qingfeng Pharmaceutical Group Co., Ltd. announced a licensing agreement with Merz Therapeutics GmbH, a German specialty pharmaceutical company, granting Qingfeng exclusive development and commercialization rights to Inbrija (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of on-off (OFF) episodes in adult patients with Parkinson's disease (PD) across mainland China, Hong Kong, and Macau.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66372#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66372\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66372#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2601-2.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2601-2.webp\",\"width\":1080,\"height\":608,\"caption\":\"Qingfeng Pharmaceutical Secures Greater China Rights to Merz's Inbrija Levodopa Inhalation Powder for Parkinson's Disease OFF Episodes\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66372#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Qingfeng Pharmaceutical Secures Greater China Rights to Merz&#8217;s Inbrija Levodopa Inhalation Powder for Parkinson&#8217;s Disease OFF Episodes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Qingfeng Pharmaceutical Secures Greater China Rights to Merz's Inbrija Levodopa Inhalation Powder for Parkinson's Disease OFF Episodes - Insight, China&#039;s Pharmaceutical Industry","description":"Qingfeng Pharmaceutical Group Co., Ltd. announced a licensing agreement with Merz Therapeutics GmbH, a German specialty pharmaceutical company, granting Qingfeng exclusive development and commercialization rights to Inbrija (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of on-off (OFF) episodes in adult patients with Parkinson's disease (PD) across mainland China, Hong Kong, and Macau.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66372","og_locale":"en_US","og_type":"article","og_title":"Qingfeng Pharmaceutical Secures Greater China Rights to Merz's Inbrija Levodopa Inhalation Powder for Parkinson's Disease OFF Episodes","og_description":"Qingfeng Pharmaceutical Group Co., Ltd. announced a licensing agreement with Merz Therapeutics GmbH, a German specialty pharmaceutical company, granting Qingfeng exclusive development and commercialization rights to Inbrija (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of on-off (OFF) episodes in adult patients with Parkinson's disease (PD) across mainland China, Hong Kong, and Macau.","og_url":"https:\/\/flcube.com\/?p=66372","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-26T14:10:49+00:00","article_modified_time":"2026-05-26T14:10:51+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2601-2.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66372#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66372"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Qingfeng Pharmaceutical Secures Greater China Rights to Merz&#8217;s Inbrija Levodopa Inhalation Powder for Parkinson&#8217;s Disease OFF Episodes","datePublished":"2026-05-26T14:10:49+00:00","dateModified":"2026-05-26T14:10:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66372"},"wordCount":497,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=66372#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2601-2.webp","keywords":["Merz Therapeutics","Qingfeng Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66372#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66372","url":"https:\/\/flcube.com\/?p=66372","name":"Qingfeng Pharmaceutical Secures Greater China Rights to Merz's Inbrija Levodopa Inhalation Powder for Parkinson's Disease OFF Episodes - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=66372#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=66372#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2601-2.webp","datePublished":"2026-05-26T14:10:49+00:00","dateModified":"2026-05-26T14:10:51+00:00","description":"Qingfeng Pharmaceutical Group Co., Ltd. announced a licensing agreement with Merz Therapeutics GmbH, a German specialty pharmaceutical company, granting Qingfeng exclusive development and commercialization rights to Inbrija (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of on-off (OFF) episodes in adult patients with Parkinson's disease (PD) across mainland China, Hong Kong, and Macau.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66372#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66372"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=66372#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2601-2.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2601-2.webp","width":1080,"height":608,"caption":"Qingfeng Pharmaceutical Secures Greater China Rights to Merz's Inbrija Levodopa Inhalation Powder for Parkinson's Disease OFF Episodes"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66372#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Qingfeng Pharmaceutical Secures Greater China Rights to Merz&#8217;s Inbrija Levodopa Inhalation Powder for Parkinson&#8217;s Disease OFF Episodes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2601-2.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66372","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66372"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66372\/revisions"}],"predecessor-version":[{"id":66374,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66372\/revisions\/66374"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/66373"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66372"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66372"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66372"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}